Developmental Research in Cancer Prognosis and Prediction (R21)

Post Date

April 14th 2009

Application Due Date

May 7th 2012

Funding Opportunity Number

PA-09-158

CFDA Number(s)

93.394
93.395

Funding Instrument Type(s)

Grant

Funding Activity Categories

Education
Health

Eligibility Categories

State Governments
County Governments
City or Township Governments
Special District Governments
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Funding

• Award Range:

  $None - $200000

Grant Description

Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), encourages research applications from institutions and organizations to evaluate the utility and pilot the application of new strategies for determining prognosis or predicting response to therapy for cancer. The purpose of this FOA is to develop newly discovered biomarkers from initial correlative observations into assays or test systems suitable for use in clinical trials or other types of confirmatory clinical research studies. This program will provide tools whose purpose is to improve clinical decision-making in the care of cancer patients. Mechanism of Support. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism and runs in parallel with a FOA of identical scientific scope, PA-09-159, that encourages applications under the Exploratory/Developmental Phase II Grant (R33) mechanism. Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism, numbers, quality, duration, and costs of the applications received.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/pa-files/PA-09-158.html